BUILDING THE RAILS FOR MEDICAID DRUG PRICING ARBITRAGE: A STARTUP BLUEPRINT FOR THE GENEROUS MODEL
Welcome to Healthcare Markets & Technology.
Rigorous analysis of AI, policy, capital, technology, and clinical operations across U.S. healthcare — written for the people who build, invest in, and lead it.
Free subscribers get 2 public articles per week. Upgrade to paid → for the full 7 articles/week, paid podcast episodes, deal breakdowns, and the complete 538-deep-dive archive.
Subscribe or upgrade here →
One thing to bookmark: the searchable Knowledge Base at kb.onhealthcare.tech isn’t in Substack’s menu. Save it now — on mobile, tap share → “Add to Home Screen.”
Reply to any email with questions. I read every one.
— Trey
Abstract
The CMS Innovation Center just dropped something genuinely interesting with the GENEROUS Model, a voluntary program that lets pharma manufacturers provide Most Favored Nation pricing to state Medicaid programs through supplemental rebates. This creates a massive coordination problem between manufacturers, states, and CMS that screams for a software infrastructure layer. This essay outlines a business plan and technical architecture for a startup that becomes the operational backbone of GENEROUS, positioning itself as the essential middleware between all parties while building multiple revenue streams and defensible moats. The opportunity is time-sensitive given the model’s January 2026 start date and compressed negotiation timeline.
Key Topics Covered:
- Deep dive into the GENEROUS Model mechanics and market opportunity
- Business model spanning SaaS platforms, consulting services, and data products
- Technical architecture for international pricing aggregation, rebate calculation, and state invoicing systems
- Go-to-market strategy prioritizing manufacturer partnerships and state onboarding
- Competitive positioning and defensibility analysis
- Financial projections and funding requirements
- Risk factors and mitigation strategies
